CMC Biologics Inc., has entered into an agreement with Immunocore Limited, a UK-based biotechnology company focused on developing new treatments for cancer, viral infections and autoimmune diseases, for the process transfer and cGMP production of IMCgp100, Immunocore’s lead product. IMCgp100 is a novel first-in-class cancer immunotherapeutic based on proprietary platform T- cell receptor (TCR) technology. Under the agreement, CMC Biologics will transfer and scale up Immunocore’s manufacturing...